Pfizer Announces Topline Results From Two Phase 3 Trials Of LITFULO In Patients With Vitiligo; Both The 50 And 100 Milligram Doses Delivered Significant, Clinically Meaningful Improvements Over Placebo
Phase 3 trials evaluated the efficacy and safety of LITFULO once daily in patients with both active and stable nonsegmental vitiligo (NSV) and who had a broad range of disease severity. The TRANQUILLO study included
Pfizer's medicine for a skin condition called vitiligo worked better than a fake pill in two big tests. When a company's medicine passes these kinds of tests, it means the company might be able to sell it soon, which could be good for the business.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.